Phase II clinical trial of cediranib in patients with metastatic castration-resistant prostate cancer.

ABSTRACT:

Objective

To assess the efficacy and toxicity of cediranib, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, in patients with metastatic castration-resistant prostate cancer (CRPC) previously treated with docetaxel-based therapy.

Patients and methods

The study used a Simon two-stage trial design, which required at least two of 12 patients in the first cohort to be progression-free at 6 months. We enrolled a total of 35 evaluable patients who all received cediranib 20 mg orally daily. In a second cohort, 23 additional patients received prednisone 10 mg daily with cediranib. Endpoints included tumour response, progression-free survival (PFS), overall survival (OS), vascular permeability via dynamic contrast-enhanced magnetic resonance

SUBMITTER: Dahut WL 

PROVIDER: S-EPMC3660464 | biostudies-literature | 2013 Jun

REPOSITORIES: biostudies-literature